Pfizer Inc. Treading Water Ahead Of Clinical Data

Clinical data, not quarterly results, are the driving force for Pfizer today.

Jan 29, 2014 at 6:30PM

The Street almost seems to be processing the quarterly reports from Big Pharma companies like Bristol-Myers Squibb and Pfizer (NYSE:PFE) as annoying opening acts that just have to be tolerated before the headliner goes on stage. With that in mind, Pfizer's decent fourth quarter results aren't likely to matter as much as upcoming clinical trial results from studies of palbociclib ("palbo"), Prevnar, and Xeljanz that could collectively point the way toward over $10 billion in long-term revenue.

Not a lot expected, slightly more delivered
Pfizer reported that revenue fell 3% as reported this quarter, good enough to beat the average Wall Street guess by about 1%. Although the company's emerging market revenue growth was a bright spot (up 9% to about $2.7 billion) and products like Lyrica (up 11%), Prevnar (up 3%), and Enbrel (up 5%) did a little better than expected, there just aren't enough large new drugs to move the needle all that much. Consumer health was up 1%, missing estimates and continuing an uninspiring trend.

Margin performance was likewise so-so. Gross margin was a little better than expected, but still down a half-point. Operating income was on target, but down 3% from last year.

All told, it's difficult to get excited about Pfizer's current performance. This slowdown has long been expected, but the fact remains that Pfizer is well behind Bristol-Myers Squibb (revenue up 6%) and Johnson & Johnson (NYSE: JNJ) (up 12%) when it comes to sales growth. Pfizer still has excellent margins by industry standards (an operating margin 10 points higher than Bristol-Myers, and well ahead of others like Lilly and Novartis), but the problem is that Wall Street never seems to reward maintaining excellence as much as attaining it.

Data on the way
If current results don't give investors all that much to cheer or pay attention to, the same cannot be said of upcoming clinical data releases. Over the next few months Pfizer is expected to report Phase II data on palbociclib in breast cancer, Phase III data on Xeljanz in psoriasis, Phase II data on the company's PCSK9 cholesterol drug (likely at the March ACC meeting), and data from the company's CAPITA study of the Prevnar vaccine.

Palbociclib may or may not be the most valuable asset in the company's pipeline (clinical data will decide that), but it is certainly the one for which the expectations are highest. The pharma industry has been working on CDK inhibitors for two decades, and this one may finally be the real deal. While the primary indication is breast cancer, Pfizer will be exploring the efficacy of the drug in other cancer types and many analysts have already penciled this one in as a $5 billion drug in 2020. With Pfizer's position in the evolving immuno-oncology market not as strong at present as that of Bristol-Myers, and perhaps Novartis, strong results are important to the share price.

Palbociclib is the headliner, but these other drugs are not trivial add-ins. Xeljanz is addressing a market that is worth billions and, while it may never beat out biologics, success in psoriasis would help it on its why to the $2 billion or more in sales that many already expect.

OTC Lipitor and a split are further off
I've written previously that I do not see a lot of automatic inherent value in Pfizer's decision to split the company into three different operations (one "value", two "innovative"). Were the split to lead to the acquisition of the value segment by a company like Mylan or Valeant, that could be a different story. Mylan's strong manufacturing base and existing relationship with Pfizer could make such a deal worthwhile, and Valeant could leverage its low tax base to generate value from a deal and advance its plans to become a big pharma, though a mature, developed-market focused business is not really what they seem to want these days.

Last and not least is the possibility of over-the-counter (OTC) Lipitor. Pfizer is running a 1,200-patient Phase III study of the lowest dose form of Lipitor (10 mg) and could file with the FDA to sell it as an OTC drug in 2015. The FDA is likely to be sensitive to the risk of such a move, and I'm not sure about the economic argument of selling a drug OTC for $30 or $40/month when the co-pay for the generic version is often less than $10. However, stranger things have happened.

The bottom line
I don't hate Pfizer at this price, but neither do I have any particular love for it. While I do believe that drugs like palbo, Prevnar (a vaccine), and Xeljanz can all contribute to more than $10 billion in pipeline-based sales in 2020, I'm only looking for long-term revenue growth of about 1% as these new/growing drugs offset older drugs lost to generic competition. I do expect free cash flow growth to exceed sales growth, but that only gets me to $32 in fair value in my model.

Including Pfizer's dividend, that's good enough for an annual expected return in-line or slightly better than the overall market. That makes Pfizer a decent enough hold, but perhaps not the most compelling idea for new money.

Dividend stocks to rely on
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Valeant Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers